Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (pf 0495061), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects
Latest Information Update: 09 Oct 2023
At a glance
- Drugs Bococizumab (Primary)
- Indications Cardiovascular disorders
- Focus Registrational; Therapeutic Use
- Acronyms SPIRE-2
- Sponsors Pfizer
- 28 Aug 2023 Results (n=190) assessing the potential anti-inflammatory effects of PCSK9 inhibition using plasma proteomics from SPIRE-1/2 trials, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 08 Jan 2021 Results from CANTOS, JUPITER, SPIRE-1, SPIRE-2, and CIRT trials published in the European Heart Journal